Important information regarding cookies and
By using this website, you consent to the use of cookies in accordance with the IMB Cookie Policy. For more information on cookies, see our Cookie Policy.
Full Version | Search

The Irish Medicines Board -

IMB Logo

Tolvaptan (Samsca) - Important Safety Information from Otsuka as approved by the Irish Medicines Board

03 April 2012

Important Safety Information communication from Otsuka on the risks of increases in serum sodium which are too rapid when using Tolvaptan (Samsca) and how to minimise the risks.

Important Safety Information - Tolvaptan (Samsca)

Date Printed: 24 April 2014

© Irish Medicines Board 2014 | Developed by Engine Solutions

Address: Kevin O'Malley House, Earlsfort Centre, Earlsfort Terrace, Dublin 2, Ireland.
Tel: 353-1-676 4971